Pharmacokinetic optimization of antiretroviral therapy in pregnancy. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

http://www.wikidata.org/entity/Q38047214

about

Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.The association between HIV (treatment), pregnancy serum lipid concentrations and pregnancy outcomes: a systematic review Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Pharmacokinetics of tenofovir during pregnancy and postpartum.Basic obstetric pharmacology.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.Unexpected vertical transmission of HIV infection.Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method.Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective

P2860

Q33748099-EB41CF86-3CEF-4207-B317-12F3AAF90B18 Q33893572-8AFDD840-AA02-4168-BD75-45ACCFAFB22A Q34710705-F5B3860A-7D8E-4C87-A48C-24B4D799059E Q36888597-BE8CFE55-37B8-4818-9B65-330A35F3A825 Q38256590-79EEEB19-6343-4411-BFCB-9D1CB87D6965 Q38954109-FC8E2F3C-1022-48E6-9D83-651BBACFFD71 Q41257241-4A7FB40C-DF56-4181-81E6-5D6AD6550A5F Q41665599-FA33EA7B-EC27-4B8F-9B14-13934367054F Q42263864-7D6F54E8-516E-49A8-8DFC-667D3E016E75 Q46158508-B57D5242-ECF7-4F8F-B300-FDDADB68344E Q46460183-CD7A9231-CFC2-4B20-B2EE-E71B76204996 Q47551255-E42C217B-1215-406F-A552-604825B43C6E Q56910156-04A92444-2120-4836-9641-27B173F68E2F Q58073610-5A0657D8-3BCC-4909-B5AE-E85B3EE20D8E

P2860

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

http://www.wikidata.org/entity/Q38047214

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

@en

type

label

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

@en

prefLabel

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

@en

P1433

Q38047214-45D3C29C-4AB4-4D5D-890F-1788EB652F9C

P1476

Q38047214-4955FE0B-DA0F-4AD5-9962-ADD01246BB40

P2093

Q38047214-1DDC36C1-89C7-4607-9A2F-0C6C13D0C2C9

Q38047214-619BFD35-37D3-49EB-9DE6-20D7ED5074F4

P2860

Q38047214-023765B8-C91C-4B20-B560-F3CD77C937CC

Q38047214-0352E7D7-4E40-4F46-A764-014F14F8477E

Q38047214-037E1EC7-8D57-4A10-8577-5B30931F7867

Q38047214-075DC8CF-18A9-4739-9678-3C07C10AE0C6

Q38047214-08165AD6-F599-49EB-8079-37B8575A9AF6

Q38047214-09E4991F-044C-4BB0-8158-321697B4A543

Q38047214-0D4236D1-C2F4-42AF-B2B7-A07B1EEB9659

Q38047214-18B2824B-5B07-43B7-9C8E-46BC677BD276

Q38047214-196F63AC-083B-4AF3-AE43-491299CD9E10

Q38047214-1ADC13C6-4368-478F-899F-3621604EACC1

P2888

Q38047214-1127DB3E-8D4D-4A69-978A-447F48A8DA81

P304

Q38047214-F2CB2C1D-C981-4AB2-8C91-3EB8C3C497FA

P31

Q38047214-B7ABB261-6CEA-4AA1-AC6B-414792012864

P356

Q38047214-1B0FF002-9826-4EAE-99CA-E0A12D8A4330

P433

Q38047214-EA5AABBC-0149-4185-88E7-AAE82C4E0BF4

P478

Q38047214-D104FD78-17CF-4509-81C0-1A7CBDC10465

P50

Q38047214-1B679F71-1649-4367-AC50-174020A7ACC9

P577

Q38047214-2F880F0F-A71F-48C0-B9C3-1C3CE195EE24

P6179

Q38047214-226B2BDE-4F74-4344-9AE0-2074EBB8A171

P698

Q38047214-CC77F88B-67E9-4E0E-AAB5-3FD5DBD768A4

P921

Q38047214-137A40A9-C3B4-46BD-B5EA-BCE5D3DF5C01

P356

S40262-012-0002-0

P1433

Clinical Pharmacokinetics

P1476

Pharmacokinetic optimization of antiretroviral therapy in pregnancy

@en

P2093

Jennifer R King

http://www.w3.org/2001/XMLSchema#string

Kajal Buckoreelall

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial

HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Lopinavir protein binding in HIV-1-infected pregnant women.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.

P2888

s40262-012-0002-0

P304

639-659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-012-0002-0

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1031638232

http://www.w3.org/2001/XMLSchema#string

P698

23018528

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug